Ontology highlight
ABSTRACT:
SUBMITTER: Jonker DJ
PROVIDER: S-EPMC3139984 | biostudies-literature | 2011 Jun
REPOSITORIES: biostudies-literature
Jonker D J DJ Rosen L S LS Sawyer M B MB de Braud F F Wilding G G Sweeney C J CJ Jayson G C GC McArthur G A GA Rustin G G Goss G G Kantor J J Velasquez L L Syed S S Mokliatchouk O O Feltquate D M DM Kollia G G Nuyten D S A DSA Galbraith S S
Annals of oncology : official journal of the European Society for Medical Oncology 20101203 6
<h4>Background</h4>This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors.<h4>Patients and methods</h4>Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate. The primary objectives of this study were (in part A) dose-limiting toxicity, maximum tolerated dose (MTD) and the lowest biologically active dose level and (in part B) the optimal dose/dose range. ...[more]